Report : Plasma Fractionation Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Immunoglobulin, Albumin, Coagulation Factor Concentrates, Protease Inhibitors, Other Plasma Products); Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Other Applications); End User (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes), and Geography
According to the latest study on Plasma Fractionation Market Forecast to 2028 – COVID-19 Impact and Global Analysis - by Product, Application, and End User,” the market is projected to reach US$ 40,731.98 million by 2028 from US$ 26,575.83 million in 2021; it is expected to grow at a CAGR of 6.3% during 2021–2028. The report highlights the trends prevailing in the global plasma fractionation market, and drivers and deterrents pertaining to the market growth.
Based on product, the plasma fractionation market is segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and other plasma products. The immunoglobulin segment is expected to account for the largest share of the market in 2021. The growth of the segment is attributed to the changing medical perception toward the use of plasma therapy and immunization against infectious diseases.
The increasing application of plasma therapy and active participation of companies in market developments are driving the growth of the plasma fractionation market. However, the availability of recombinant or non-plasma counterparts restrains the market growth. Further, development potential in emerging countries offer lucrative opportunities for the growth of the global plasma fractionation market.
Bio Products Laboratory LTD, CSL Limited, Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Grifols S.A, Kedrion, SK Plasma, Plasmagen Biosciences PVT. LTD, and Octapharma AG are among the prominent players operating in the plasma fractionation market. These companies are focusing on partnerships, product launches, collaborations, and other business strategies to sustain their position in the market. For instance, in May 2020, Bio Products Laboratory launched of ALBUMINEX 5% and ALBUMINEX 25%, along with making it immediately available for supply across the US.
The plasma fractionation market is segmented on the bases of product, application, and end user. Based on product, the market is subsegmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and others. The plasma fractionation market, by application, is further segmented into neurology, immunology, hematology, critical care, pulmonology, and others. The market, based on end user, is subsegmented into hospitals and clinics, clinical research laboratories, and academic institutes.
In terms of geography, the medical aesthetics market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, India, Japan, South Korea, and Rest of APAC), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and Rest of MEA), and South and Central America (Brazil, Argentina, and Rest of SCAM).
Contact Person: Sameer Joshi
Email Id: email@example.com